TC Biopharm Investor Relations Material
Latest events
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
TC Biopharm Plc is a UK-based clinical-stage biotechnology company developing cell-based immunotherapies for cancer treatment. The company focuses on gamma delta T cell therapies, aiming to treat hematologic malignancies and solid tumors. Its proprietary platform is based on allogeneic cell therapy designed for off-the-shelf use. The company is headquartered in Glasgow, United Kingdom, and its shares are listed on the OTCQB.
Latest articles
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
Ticker symbol
TCBP.Y
Country
🇺🇸 United States